TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04020302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring shopping intervention
Description: Intervention will occur once per week for a duration of 8 weeks. The intervention format will alternate between individual and group sessions, so that the first week of intervention will be provided in a group format, the second week will be provided in an individual format, and so forth. Sessions will be 90 minutes in duration. Data will be collected during individual sessions, which will occur every other week. During individual sessions, each participant will meet at the facility for the first 15 minutes, will travel to a local grocery store for 45 minutes, and then reconvene at the facility for the final 30 minutes. Group sessions will follow the same structure; however, all ten participants will be present. Each of the 8 sessions will consist of the following: awareness training; facilitation of strategy generation; facilitation of error detection; reinforcement of self-monitoring techniques; and opportunity for participants to practice self-monitoring techniques.
Study: NCT04976491

Intervention type: DIETARY_SUPPLEMENT
Intervention: CD-C-Food
Description: CD patients combined with the characteristics of Chinese diet, remove the refined food, and combined with food intolerance detection method to check the corresponding food
Study: NCT02133131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir FDC
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir FDC
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400mg tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400mg tablet taken q.d. by mouth.
Study: NCT00908375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
Study: NCT02495402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
Study: NCT02168153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic Manipulative Therapy
Description: Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list
Description: Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
Study: NCT00908375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
Study: NCT01294280

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00908362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
Study: NCT04976491

Intervention type: DIETARY_SUPPLEMENT
Intervention: EEN
Description: EEN goup received EEN continuously for 6 moths
Study: NCT01167062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride OCAS 0.4 mg
Description: One tablet OD for a maximum of 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet OD for a maximum of 28 days
Study: NCT02977715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JYNNEOS (Liquid Formulation)
Description: Two doses of attenuated live virus smallpox vaccine (JYNNEOS liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JYNNEOS (Liquid Formulation)
Description: Two doses of attenuated live virus smallpox vaccine (JYNNEOS liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JYNNEOS (Lyophilized Formulation)
Description: Two doses of attenuated live virus smallpox vaccine (JYNNEOS lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
Study: NCT03943693

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double shock
Description: Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized. If the first attempt with this approach fails to terminate atrial fibrillation a second attempt will be made using the same approach. If the second attempt fails the dual shock approach will be considered to have failed and further treatment will be determined by the primary team/attending cardiologist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single shock
Description: Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only. A repeat attempt will be made using the same approach if the initial shock fails. If the second attempt fails, the single shock approach will be considered to have failed. Patients will be crossed over to dual shock therapy while under the same sedation episode. For cross-over patients, two near-simultaneous 200-Joule shocks will be delivered through the two sets of pads already in position. If this fails further treatment will be determined by the primary team/attending cardiologist.
Study: NCT00226577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (GemzarR) 1500 mg/m2
Study: NCT03793907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear Fitbit
Study: NCT00908362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol
Description: Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
Study: NCT00381680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaspargase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: Given PO
Study: NCT02110966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine plus Tramadol
Description: 0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
Study: NCT03045926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmectite (Smecta®)
Study: NCT03186794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill exercise training
Description: 30 minutes of continuous treadmill walking at a target intensity or use of an interval approach in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each session will last about 60 minutes but slightly longer if an interval approach is used.
Study: NCT00700115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra + Isentress
Description: Kaletra 400/100 mg + Isentress 400 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-study antiretroviral regimen
Description: Standard doses of pre-study antiretroviral regimen
Study: NCT03628781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral tools integrated within mehealth for ADHD software
Description: Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mehealth for ADHD
Description: The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems.

Intervention type: OTHER
Group type: OTHER
Intervention: mehealth for ADHD
Description: The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems.
Study: NCT04424186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Rehabilitation for Life'
Description: An empowerment-oriented cross-sectorial program including vital sign measurement and systematic progressive rehabilitation combined with convenient access for collaboration among professionals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care and rehabilitation
Description: The care and rehabilitation usual provided to patients after hip fracture surgery
Study: NCT02399046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee System made in China (Sigama, CoCr, PFC)
Description: SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee System made outside of China (Sigama, NP, PFC)
Description: SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
Study: NCT02066909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15 mg PF-06649751
Description: Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg PF-06649751
Description: Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg PF-06649751
Description: Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5 mg PF-06649751
Description: Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5 mg PF-06649751 21 Days
Description: Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.0 mg PF-06649751
Description: Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5.0 mg PF-06649751
Description: Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.0 mg PF-06649751
Description: Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5 mg PF-06649751 in healthy Japanese subjects
Description: Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
Study: NCT04493255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]E7090
Description: \[14C\]E7090, oral capsule.
Study: NCT04096716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept
Description: Tc-99m tilmanocept is a radioactive diagnostic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept
Description: Tc-99m tilmanocept is a radioactive diagnostic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept
Description: Tc-99m tilmanocept is a radioactive diagnostic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept
Description: Tc-99m tilmanocept is a radioactive diagnostic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept
Description: Tc-99m tilmanocept is a radioactive diagnostic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept
Description: Tc-99m tilmanocept is a radioactive diagnostic agent.
Study: NCT03754595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopic pancreatoduodenectomy
Description: Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopic pancreatoduodenectomy
Description: 2D Laparoscopic pancreatoduodenectomy
Study: NCT00591916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]
Description: Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]
Description: Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]
Description: Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
Study: NCT02616458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ear pain counseling
Description: The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: language power counseling
Description: The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
Study: NCT02307695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: saxagliptin 5 mg p.o. qd, 24 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician.
Study: NCT02101957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP103

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03865550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Solution
Description: Active comparator